임상시험 트래커

추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov

17건 표시

3상모집 예정· Varicella (Chickenpox)
SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years
리드: SK바이오사이언스
상세 →NCT07415252
1/2상모집 중· Healthy Participants
A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.
리드: SK바이오사이언스
상세 →NCT07280858
1/2상모집 중· Japanese Encephalitis Virus Disease
A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults
리드: SK바이오사이언스
상세 →NCT06680128
단계 미표기철회· COVID-19
A Blood Collection Study to Assess the Immunogenicity of Nationally Authorized Homologous COVID-19 Booster Vaccines Among Adult Vaccinees.
리드: SK바이오사이언스
상세 →NCT05710289
3상완료· COVID-19
Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older
리드: SK바이오사이언스
상세 →NCT05501522
3상완료· Covid19
Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19)
리드: SK바이오사이언스
상세 →NCT05007951
2상완료· Rotavirus Vaccine
Mixed Schedule Study of Live Oral Rotavirus Vaccines and Trivalent P2-VP8 Subunit Rotavirus Vaccine
협력: SK바이오사이언스
상세 →NCT04344054
1/2상상태 미확인· COVID-19 (Healthy Volunteers)
Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (COVID-19)
리드: SK바이오사이언스
상세 →NCT04750343
1/2상완료· COVID-19 (Healthy Volunteers)
Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19)
리드: SK바이오사이언스
상세 →NCT04742738
1상완료· COVID-19 (Healthy Volunteers)
Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19)
리드: SK바이오사이언스
상세 →NCT04760743
3상완료· Typhoid
Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)
협력: SK바이오사이언스
상세 →NCT04204096
3상상태 미확인· Typhoid
Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine
협력: SK바이오사이언스
상세 →NCT03933098
3상상태 미확인· Rotavirus Infection of Children
A Trial to Assess the Safety, Immunogenicity and Efficacy of a Trivalent Rotavirus P2-VP8 Subunit Vaccine in Prevention of Severe Rotavirus Gastroenteritis in Healthy Infants in Africa and India
협력: SK바이오사이언스
상세 →NCT04010448
1/2상완료· Cervical Cancer
Immunogenicity and Safety Study of NBP615 in Healthy Female
리드: SK바이오사이언스
상세 →NCT04453241
3상완료· Influenza
Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months
리드: SK바이오사이언스
상세 →NCT03704740
2상완료· Typhoid
Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine
협력: SK바이오사이언스
상세 →NCT03527355
3상완료· Varicella
Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age
리드: SK바이오사이언스
상세 →NCT03114943

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.